This ExpertREACT article was originally published on 11 February 2009. Financial results and market positions described reflect the state of knowledge at that date.
Slower growth but still advancing
All major vaccine companies had by February 2009 reported their full year 2008 results. VacZine Analytics calculated that the top five vaccine players sold approximately $17.5bn in 2008 - a 5-7% increase on 2007 in reported terms. This was significantly lower than the approximately 40% growth seen in 2007 over 2006, and reflected two key dynamics: a substantial impact from an appreciating US dollar reducing the reported dollar value of Euro and Sterling-denominated sales (particularly for GSK and Sanofi Pasteur), and the continued maturation of Gardasil - still the industry's most discussed vaccine - which recorded an estimated 5% decline in 2008 at $1.4bn. On a comparable exchange-rate basis, underlying growth was closer to 20%, more consistent with the industry's longer-term CAGR.
The top-selling vaccine products of 2008 included Gardasil and Wyeth's pneumococcal vaccine Prevnar (PCV-7, $2.7bn, +8-10%). As a single entity GSK Biologicals reported the highest dollar sales at $4,697m - approximately 18% growth on 2007 - with Rotarix and Cervarix among the growth drivers. Merck & Co's vaccine revenues were flat to slightly declining as Gardasil's US growth flattened and competition from the European SPMSD joint venture created accounting complexities. Subject to shareholder approval, Wyeth was expected to become part of an enlarged Pfizer group by mid-2009, with major implications for the competitive landscape around Prevnar and PCV-13.
Setting the stage for 2009
VacZine Analytics' outlook for 2009 highlighted the potential for the Pfizer-Wyeth merger to reshape competitive dynamics, expected meningococcal ACWY launches (Menveo, Menhibrix, expanded Menactra), and the continued international expansion of Gardasil and Cervarix as the major commercial themes. The H1N1 pandemic - which would transform industry fortunes by mid-year - was of course not yet on the horizon at the time of this analysis, making 2009 the most surprising year the industry would experience for a generation.